NCT05287399 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

December 20, 2024

Study Completion Date

December 20, 2024

Conditions

Advanced Solid Tumors

Interventions

DRUG

ASC61 200 mg 1

200mg of ASC61 orally once daily for cycles of 28 days

DRUG

ASC61 200 mg 2

200 mg of ASC61 orally twice daily for cycles of 28 days

DRUG

ASC61 300 mg

300 mg of ASC61 orally twice daily for cycles of 28 days

DRUG

ASC61 400 mg

400 mg of ASC61 orally twice daily for cycles of 28 days

DRUG

ASC61 600 mg

600 mg of ASC61 orally twice daily for cycles of 28 days

Trial Locations (4)

RECRUITING

Nebraska Cancer Specialists, Omaha

RECRUITING

California Cancer Associates for Research & Excellence (cCARE), Encinitas

RECRUITING

California Cancer Associates for Research & Excellence (cCARE), San Marcos

RECRUITING

California Cancer Associates for Research & Excellence (cCARE), Fresno